about
Regulation of Natural Killer Cell Function by STAT3Glycosyl-Phosphatidyl-Inositol (GPI)-Anchors and Metalloproteases: Their Roles in the Regulation of Exosome Composition and NKG2D-Mediated Immune RecognitionNKp46(+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in miceNKG2D CARs as cell therapy for cancer.MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus.Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells.Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.NKG2D Receptor and Its Ligands in Host DefenseNKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCTOrchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.Increased Bacterial Load and Expression of Antimicrobial Peptides in Skin of Barrier-Deficient Mice with Reduced Cancer Susceptibility.Autoantibody Profiles in Collagen Disease Patients with Interstitial Lung Disease (ILD): Antibodies to Major Histocompatibility Complex Class I-Related Chain A (MICA) as Markers of ILD.Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association studyPotential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cellsThe RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancerExpression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function declineThe immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma.The anti-tumor role of NK cells in vivo pre-activated and re-stimulated by interleukins in acute lymphoblastic leukemia.Cell transfer therapy for cancer: past, present, and future.Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma.Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretionMechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.Role of NKG2D in cytokine-induced killer cells against lung cancer.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.Intercellular Communication of Tumor Cells and Immune Cells after Exposure to Different Ionizing Radiation Qualities.Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells.Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity.Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemiaAnti-NKG2D mAb: A New Treatment for Crohn's Disease?Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.
P2860
Q26752551-8C19B31F-1B07-4314-99C1-06C2EABA53B0Q28076151-15109364-C629-4AEC-9B48-1754F40E0180Q30277911-7F0CE520-7282-4C8C-9E66-B381CD494A25Q33595873-A44D94C9-DCDF-45AD-ACAA-DE355CDE1309Q33639723-5D1683F6-19AF-44CB-91AE-E13F5C08052EQ33676231-F36E413F-4273-491E-B37D-C6618C575BC0Q33682274-69D01CEF-3D3D-43EB-9F72-0AD9C4E03D06Q34301698-831474C8-2D5A-4F5F-9C8E-A3AC7D96D205Q35168522-F7C9A8DD-F5E6-4C8F-8D04-EDE7D292B7B8Q35687826-BF03C0DA-DD6B-4C77-B933-210081897363Q35692428-D757DC40-4938-4226-8FA8-2549BF5F4B17Q35783394-6D68D49B-90F0-4FA9-8103-9878089FB67BQ35893302-B5AEDD46-6F5B-4F07-B4D3-7997D64B5173Q35962818-FCF50F86-E287-4BA2-97F4-6882A462C634Q36211604-CFD758EC-D164-428A-8476-B89D0FA98BCDQ36212699-C23FFBE2-7F45-46BC-8336-ACEAAEBCE408Q36723387-0B4D40F3-08D1-45DD-B0F4-85C227E0F1E9Q37086056-4E347659-C992-41A2-9306-439CE6320A66Q37137278-1C321F16-4D54-4032-BCAC-C2628382C8C6Q37316220-B2197820-1CA7-4A04-8441-9C3782E5E463Q37622429-2FB00C92-48A6-4E4D-B836-0C2524DD2E2FQ37694772-E8C97796-259E-4F76-9089-7FBB35ADF2E6Q38205228-0CD07443-FD7E-4581-B14D-E42147847952Q38376092-5AD5455F-A1B9-4F8F-B203-FA5710E85FADQ38634034-9018CF60-4221-456F-A2B9-E40337049F58Q38706890-F5223DAD-5A28-4BF9-9F00-71846527BDC6Q38730881-14961CC4-F97A-4298-9636-405900E1F9AAQ38772095-A10D6393-2AAA-4C5E-99EA-899C98855782Q38783833-DBCAA339-1900-4DFA-A585-072BCDFBFA3EQ38788557-0B5C713F-976C-4370-BA0D-EDA4012CEF66Q38830813-DE61D5FD-5E9C-4DB7-A481-C8FC9A768F26Q38860610-C7F03533-34CB-4DDC-9246-52AB22D38B1EQ39389306-DA5EF6B6-4476-44CB-A15A-486F5A445640Q40348935-AE22690E-66E3-421E-9B9E-E5AC496CD166Q40749737-B719FBF1-1C84-430A-B3A8-12D345D53753Q41367801-A4B7EE62-F286-4175-BBAA-444B90B6711EQ41558781-A4A7A8A8-CD3A-463B-AA7A-D27886EC91C1Q41660377-061F7039-7814-4ACC-A108-BF4A7C8DEE38Q44243898-7CEA6688-5580-4D5D-B4D7-CAC8D2A0CDADQ45160655-46EADBC5-C1CE-4C00-B249-5C5574986A57
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
NKG2D ligands as therapeutic targets
@ast
NKG2D ligands as therapeutic targets
@en
NKG2D ligands as therapeutic targets
@nl
type
label
NKG2D ligands as therapeutic targets
@ast
NKG2D ligands as therapeutic targets
@en
NKG2D ligands as therapeutic targets
@nl
prefLabel
NKG2D ligands as therapeutic targets
@ast
NKG2D ligands as therapeutic targets
@en
NKG2D ligands as therapeutic targets
@nl
P2093
P2860
P3181
P1433
P1476
NKG2D ligands as therapeutic targets
@en
P2093
P2860
P3181
P407
P577
2013-01-01T00:00:00Z